PriceTargets.com logo

NASDAQ:DOCS - Doximity Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.92
  • Forecasted Upside: 51.83 %
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$31.56 As of 05/20/2022 01:00 AM ET
▼ -0.96 (-2.95%)

This chart shows the closing price for DOCS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Doximity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DOCS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DOCS

Analyst Price Target is $47.92
▲ +51.83% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Doximity in the last 3 months. The average price target is $47.92, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 51.83% upside from the last price of $31.56.

This chart shows the closing price for DOCS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in Doximity.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/25/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/23/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/21/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/22/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2022Piper SandlerLower Price Target$81.00 ➝ $44.00High
5/18/2022Canaccord Genuity GroupLower Price Target$65.00 ➝ $44.00High
5/18/2022Jefferies Financial GroupLower Price TargetBuy$78.00 ➝ $46.00High
5/18/2022Bank of AmericaLower Price TargetNeutral$55.00 ➝ $36.00High
5/18/2022GuggenheimLower Price TargetBuy$70.00 ➝ $52.00High
5/18/2022Needham & Company LLCLower Price TargetBuy$70.00 ➝ $45.00High
5/18/2022The Goldman Sachs GroupLower Price TargetBuy$72.00 ➝ $56.00High
5/18/2022Morgan StanleyLower Price TargetEqual Weight$55.00 ➝ $35.00High
5/18/2022Raymond JamesLower Price Target$60.00 ➝ $40.00High
5/18/2022Robert W. BairdLower Price Target$68.00 ➝ $45.00High
4/6/2022GuggenheimInitiated CoverageBuy$70.00Low
4/4/2022Bank of AmericaInitiated CoverageNeutral$55.00Low
3/23/2022Morgan StanleyLower Price TargetEqual Weight$62.00 ➝ $55.00Medium
2/11/2022The Goldman Sachs GroupInitiated CoverageBuy$74.00High
2/9/2022Needham & Company LLCLower Price TargetBuy$90.00 ➝ $70.00High
2/9/2022Raymond JamesLower Price TargetOutperform$80.00 ➝ $60.00High
12/17/2021Morgan StanleyLower Price TargetEqual Weight$72.00 ➝ $58.00Low
12/14/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$70.00 ➝ $60.00Medium
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$78.00High
11/16/2021Robert W. BairdInitiated CoverageOutperform$84.00Low
11/10/2021The Goldman Sachs GroupBoost Price TargetNeutral$40.00 ➝ $45.00High
11/10/2021Morgan StanleyBoost Price TargetEqual Weight$71.00 ➝ $72.00High
11/10/2021Raymond JamesBoost Price TargetOutperform$62.00 ➝ $80.00High
11/10/2021SVB LeerinkBoost Price TargetOutperform$65.00 ➝ $72.00High
11/10/2021Needham & Company LLCBoost Price TargetBuy$62.00 ➝ $90.00High
11/10/2021Piper SandlerBoost Price TargetOverweight$68.00 ➝ $81.00High
8/31/2021Morgan StanleyBoost Price TargetEqual Weight$52.00 ➝ $71.00High
8/26/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$70.00High
8/11/2021Raymond JamesBoost Price TargetOutperform$60.00 ➝ $62.00High
7/19/2021Needham & Company LLCInitiated CoverageBuy$62.00High
7/19/2021JPMorgan Chase & Co.Initiated CoverageOverweight$60.00High
7/19/2021Raymond JamesInitiated CoverageOutperform$60.00High
7/19/2021Morgan StanleyInitiated CoverageEqual Weight$52.00High
7/19/2021William BlairInitiated CoverageOutperformHigh
7/19/2021SVB LeerinkInitiated CoverageOutperform$65.00High
7/19/2021The Goldman Sachs GroupInitiated CoverageNeutralHigh
7/19/2021Piper SandlerInitiated CoverageOverweight$68.00High
(Data available from 5/22/2017 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2021
  • 7 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2021
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2021
  • 5 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/22/2022
  • 12 very positive mentions
  • 30 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
2/21/2022
  • 3 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/23/2022
  • 4 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/22/2022
  • 4 very positive mentions
  • 30 positive mentions
  • 9 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2022

Current Sentiment

  • 4 very positive mentions
  • 30 positive mentions
  • 9 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Doximity logo
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical companies and health systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $31.56
Low: $29.94
High: $32.72

50 Day Range

MA: $44.48
Low: $28.46
High: $54.00

52 Week Range

Now: $31.56
Low: $27.06
High: $107.79

Volume

2,866,485 shs

Average Volume

3,346,843 shs

Market Capitalization

$6.04 billion

P/E Ratio

45.74

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Doximity?

The following sell-side analysts have issued reports on Doximity in the last twelve months: Bank of America Co., Canaccord Genuity Group Inc., Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James, Robert W. Baird, SVB Leerink LLC, The Goldman Sachs Group, Inc., William Blair, and Zacks Investment Research.
View the latest analyst ratings for DOCS.

What is the current price target for Doximity?

0 Wall Street analysts have set twelve-month price targets for Doximity in the last year. Their average twelve-month price target is $47.92, suggesting a possible upside of 51.8%.
View the latest price targets for DOCS.

What is the current consensus analyst rating for Doximity?

Doximity currently has 1 sell rating, 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DOCS will outperform the market and that investors should add to their positions of Doximity.
View the latest ratings for DOCS.

What other companies compete with Doximity?

Other companies that are similar to Doximity include NTT DATA, Zscaler, EPAM Systems, VeriSign, OBIC Co.,Ltd., Aspen Technology, Amdocs, Endava, GEMALTO NV/S, Thoughtworks, Perficient, Compass, CI&T, Nexters and PROS. Learn More about companies similar to Doximity.

How do I contact Doximity's investor relations team?

The company's listed phone number is 650-549-4330 and its investor relations email address is [email protected] The official website for Doximity is www.doximity.com. Learn More about contacing Doximity investor relations.